{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_6566344_B1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"139-723-065-719-084"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11855,"type":"PATENT","title":"University of Montpellier Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11808,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8467,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
Search Applicants and Owners separately:univ* AND Montpellier. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1289
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO—aryl, —CO—alkoxyalkyl, —CO—aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 , wherein the β-L-2′-deoxycytidine is at least 95% in its designated enantiomeric form."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of β-L-2′-deoxythymidine of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO—aryl, —CO—alkoxyalkyl, —CO—aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3 , wherein the β-L-2′-deoxythymidine is at least 95% in its designated enantiomeric form."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus in a human comprising administering a effective combination of the compounds:
or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or acyl."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO—aryl, —CO—alkoxyalkyl, —CO—aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug;
in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3 TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1 -yl)- 1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO—aryl, —CO—alkoxyalkyl, —CO—aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug;
in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1 -yl)- 1,3 -oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a a human comprising administering an effective amount of β-L-2′-deoxycytidine of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO—aryl, —CO—alkoxyalkyl, —CO—aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of β-L-2′-deoxythymidine of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus in a human comprising administering a effective combination of the compounds
or a pharmaceutically acceptable prodrug thereof, wherein R is hydrogen or acyl."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmgaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO—alkyl, —CO-aryl, —CO—alkoxyalkyl, -CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug;
in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1 -yl)- 1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug;
in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), P-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1,3-oxathiolane (FTC)."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of famciclovir."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of penciclovir."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil)."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of ganciclovir."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of ribavirin."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-L-2-hydroxymethyl-5-(cytosin- 1-yl)- 1,3-oxathiolane (3TC)."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)- 1,3-oxathiolane (FTC)."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of famciclovir."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of penciclovir."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyc lopentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil)."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of ganciclovir."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of H, —CO-alkyl, —CO-aryl, —CO-alkoxyalkyl, —CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate and a stabilized nucleotide prodrug; in combination or alternation with an effective amount of ribavirin."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 35 , wherein the amino acid is L-valinyl."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of clam 37 , wherein the amino acid is L-valinyl."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus in a human comprising administering a effective combination of the compounds
or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an amino acid acyl residue."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 39 , wherein the amino acid is L-valinyl."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1 ,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41 or 42 , wherein the amino acid is L-valinyl."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of compound of the formula:
or a pharmaceutically acceptable prodrug thereof, wherein R is an amino acid acyl residue."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 44 , wherein the amino acid is L-valinyl."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of compound of the formula:
or a pharmaceutically acceptable prodrug thereof, wherein R is an amino acid acyl residue."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 46 , wherein the amino acid is L-valinyl."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus in a human comprising administering a effective combination of the compounds
or a pharmaceutically acceptable prodrug thereof, wherein R is hydrogen or an amino acid acyl residue."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["The method of claimn 48 , wherein the amino acid is L-valinyl."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable prodrug thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diarninopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino- 1,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["A method for the prophylaxis of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable prodrug thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a compound selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin- 1-yl)- 1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 50 or 51 wherein the amino acid is L-valinyl."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC)."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of famciclovir."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a penciclovir."],"number":58,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":59,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 9-[2-(phosphono-methoxy)ethyl]adenine (PNEA, adefovir, dipivoxil)."],"number":60,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":61,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of ganciclovir."],"number":62,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of ribavirin."],"number":63,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":64,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1 ,3-oxathiolane (FTC)."],"number":65,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":66,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":67,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of famciclovir."],"number":68,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmnaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of a penciclovir."],"number":69,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxy-methyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":70,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxi1)."],"number":71,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":72,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of ganciclovir."],"number":73,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a hepatitis B virus infection in a human comprising administering an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein R is an amino acid acyl residue; in combination or alternation with an effective amount of ribavirin."],"number":74,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 53 or 74 , wherein the amino acid is L-valinyl."],"number":75,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3 TC)."],"number":76,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathio-lane (FTC)."],"number":77,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":78,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":79,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with famciclovir."],"number":80,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with penciclovir."],"number":81,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclo-pentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":82,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil)."],"number":83,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":84,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with ganciclovir."],"number":85,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with ribavirin."],"number":86,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)."],"number":87,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula: or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathio-lane (FTC)."],"number":88,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU)."],"number":89,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with β-D-2,6-diaminopurine dioxolane (DAPD)."],"number":90,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with famciclovir."],"number":91,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with penciclovir."],"number":92,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclo-pentyl]-6H-purin-6-one (entecavir, BMS-200475)."],"number":93,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil)."],"number":94,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir)."],"number":95,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with ganciclovir."],"number":96,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising an effective amount of a compound of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier, with ribavirin."],"number":97,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating a human infected with hepatitis B comprising administering an effective amount of β-L-2′-deoxycytidine of the formula:
or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier."],"number":98,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 98 , wherein the method further comprises administering the β-L-2′-deoxycytidine in combination with a pharmaceutically acceptable carrier."],"number":99,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 98 , wherein the method further comprises administering the β-L-2′-deoxycytidine, optionally with a pharmaceutically acceptable carrier, in combination or alternation with another anti-HBV agent."],"number":100,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim wherein the anti-HBV agent is selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)- 1,3 -oxathiolane (FTC), β-L-2 ′- fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino- 1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PNEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and fibavifin."],"number":101,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating a human infected with hepatitis B comprising administering an effective amount of β-L-2′-deoxythymidine of the formula:
or its pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier."],"number":102,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 102 , wherein the method further comprises administering the β-L-2′-deoxycytidine in combination with a pharmaceutically acceptable carrier."],"number":103,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 102 wherein the method further comprises administering the β-L-2′-deoxycytidine, optionally with a pharmaceutically acceptable carrier, in combination or alternation with another anti-HBV agent."],"number":104,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 104 , wherein the anti-HBV agent is selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin- 1-yl)-1,3 -oxathiolane (FTC), β-L-2′- fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), P-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil); 9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir and ribavirin."],"number":105,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}